New facility at the existing facility in Milford, MA, USA will significantly expand cGMP manufacturing capabilities and accelerate the clinical and commercial supply of vital biopharmaceuticals
Pharmaceutical Cleanroom Industry Articles
Ecolab Opens Healthcare Advanced Design Center to Drive Innovation for the Medical Device Industry
Ecolab Inc., the global leader in water, hygiene and infection prevention solutions and services, is opening the Ecolab Healthcare Advanced Design Center in Eagan, Minn.
Picocyl Expands Product Line and Production Capacity as Demand for Pico-Cylinders Soars
As new and novel drug therapies are developed to address areas where conventional medicines are limited, drug delivery innovators, designers and manufacturers have turned to Picocyl for its unique, patented power solutions for drug and implant delivery systems.
Antimicrobial Peptide Production Induced by Nanofiber-Based Wound Dressings
Nanofiber-based wound dressings loaded with vitamin D spur the production of an antimicrobial peptide, a key step forward in the battle against surgical site infections, or SSIs. The findings by Oregon State University researchers and other collaborators, published Wednesday in Nanomedicine, are important because SSIs are the most common healthcare-associated infection and result in widespread human suffering and economic loss.
Pharmaceutical Plant in Skidel to Open in October
pharmaceutical plant in Skidel (Grodno Oblast) will be launched in October, the press service of the Council of Republic told BelTA following the meeting between Speaker, curator of the Belarusian-Indian cooperation Mikhail Myasnikovich and Indian investors Jayant Kaushik, Alok Kumar (Lok-Beta Pharmaceuticals (I) Pvt. Ltd) and Director of OOO Novalok Kumar Manoranjan.
R&D Operations Hub to Open in Chengdu, China
R&D Operations Hub to Open in Chengdu, China Sanofi to further accelerate its scientific presence with the opening...
Catalent Signs Agreement To Acquire Juniper Pharmaceuticals, Inc.
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has agreed to acquire Juniper Pharmaceuticals, Inc. (NASDAQ: JNPR), including its Nottingham, U.K.-based Juniper Pharma Services division.
Biosensor Chips based on Copper and Graphene Oxide
Russian researchers from the Moscow Institute of Physics and Technology have developed biosensor chips of unprecedented sensitivity, which are based on copper instead of the conventionally used gold. Besides making the device somewhat cheaper, this innovation will facilitate the manufacturing process.
Cardiology Laboratory Serves Bayer Strategic Alliance
Bayer Strategic Partnership formed. Bayer and the Broad Institute of MIT and Harvard announced the launch of the joint Precision Cardiology Laboratory, which will pursue novel scientific insights to enable the development of new therapies for patients with cardiovascular diseases such as heart failure.
Machine Learning Sifts & Searches Complex Scientific Data
A team of researchers from the Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab) and UC Berkeley are developing innovative machine learning tools to pull contextual information from scientific datasets and automatically generate metadata tags for each file. Scientists can then search these files via a web-based search engine for scientific data, called Science Search, that the Berkeley team is building.
MOF Nanoparticles Used to Deliver Killer Protein to Cancer
In our design, self-assembly of MOF nanoparticles and encapsulation of proteins are achieved simultaneously through a one-pot approach in aqueous environment. The enriched metal affinity sites on MOF surfaces act like the buttonhook, so the extracellular vesicle membrane can be easily buckled on the MOF nanoparticles.
Vertex Pharmaceuticals Acquires CTP-656 from Concert Pharmaceuticals for the Treatment of Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has signed a definitive asset purchase agreement to acquire CTP-656 from Concert Pharmaceuticals (Nasdaq: CNCE). CTP-656 is an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators that treat the underlying cause of cystic fibrosis (CF). As part of the agreement, Vertex will pay Concert $160 million in cash for all worldwide development and commercialization rights to CTP-656.